City of Hope Medical Center: Gliosarcoma trials
The registry lists 11 Gliosarcoma studies with City of Hope Medical Center as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 10Phase 2 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade GliomasActive, not recruitingNCT02192359Phase 1Results posted
- Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade GliomasCompletedNCT02015819Phase 1Results posted
- Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade GliomasWithdrawnNCT02055196Phase 1
- Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain MetastasesCompletedNCT01234740Phase 1
- A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade GliomasCompletedNCT01172964Phase 1
- Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2CompletedNCT01082926Phase 1
- A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain TumorsCompletedNCT00784914Phase 1
- Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant GliomaCompletedNCT00730613Phase 1
- Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade GliomaCompletedNCT00720564Phase 1
- Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to TreatmentCompletedNCT00544284Phase 1
- Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord TumorsCompletedNCT00541138Phase 2